Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; A real-life, nonrandomized controlled study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 5, 2015, Pages 547-555

  Zidarn, Mihaela ^a   Kosnik M ^a   Silar M ^a   Bajrovic, N ^a   Korosec P ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

allergen immunotherapy; basophil activation test; CD 63; grass pollen allergy; sustained effect

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; POLLEN ANTIGEN; STEROID; IMMUNOGLOBULIN G;

ADULT; ALLERGIC RHINITIS; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BASOPHIL; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRASS POLLEN; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; MALE; MAXIMUM PERMISSIBLE DOSE; PATIENT PREFERENCE; POLLEN ALLERGY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RHINITIS QUALITY OF LIFE QUESTIONNAIRE; SEASONAL ASTHMA; SKIN REDNESS; STEROID THERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBCUTANEOUS NODULE; SWELLING; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DESENSITIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MIDDLE AGED; POACEAE; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; TIME; YOUNG ADULT;

ADULT; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; POACEAE; RHINITIS, ALLERGIC, SEASONAL; TIME; YOUNG ADULT;

EID: 84926422074     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12581     Document Type: Article

References (25)

1. Dahl R, Andersem PS, Chivato T, Valovirta E, de Monchy J,. National prevalence of respiratory allergic disorders. Respir Med 2004; 98: 398-403.
2. Heinzerling LM, Burbach GJ, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, et al. GA2LEN skin test study I: GA2LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy 2009; 64: 1498-1506.
3. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475.
4. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138.
5. Akdis AK, Akdis M,. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127: 18-27.
6. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252-3259.
7. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121: 1120-1125.
8. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317: 71-79.
9. James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN,. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127: 509-516.
10. Nopp A, Cardell LO, Johansson SG, Oman H,. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009; 64: 811-814.
11. Lalek N, Košnik M, Šilar M, Korošec P,. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40: 1186-1193.
12. Soyer OU, Akdis M, Ring J, Behrendt H, Crameri R, Lauener R, et al. Mechanisms of peripheral tolerance to allergens. Allergy 2013; 68: 161-170.
13. Cox L, Li JT, Nelson H, Lockey R,. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120: S25-S85.
14. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN,. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000; 30: 132-140.
15. Košnik M, Šilar M, Bajrovič N, Mušič E, Korošec P,. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 2005; 60: 1401-1406.
16. Fujisawa T, Nagao M, Hiraguchi Y, et al. Biomarkers for allergen immunotherapy in cedar pollinosis. Allergol Int 2009; 58: 163-170.
17. Nestor CE, Dadfar E, Ernerudh J, Gustafsson M, Björkander J, Benson M, et al. Sublingual immunotherapy alters expression of IL-4 and its soluble and membrane-bound receptors. Allergy 2014; 69: 1564-1566.
18. Braza F, Chesne J, Castagnet S, Magnan A, Brouard S,. Regulatory functions of B cells in allergic diseases. Allergy 2014; 69: 1454-1463.
19. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S,. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1): CD001936.
20. Mosbech H, Østerballe O,. Does the effect of immunotherapy last after termination of treatment? Allergy 1988; 43: 523-529.
21. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A,. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807.
22. Brewczynski PZ, Kroon AM,. Wirksamkeit und Verträglichkeit einer Immunotherapie mit modifizierten Gräserpollenallergenen. Allergologie 1999; 22: 411-420.
23. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-433.
24. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293-300.
25. Tabar AI, Arroabarren E, Echechipia S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127: 57-63.